Probiotics for Fatty Liver Disease: Evidence

Probiotics for non-alcoholic fatty liver disease (NAFLD) have attracted growing scientific interest, largely because of the well-established link between gut bacteria and liver health. NAFLD, now increasingly termed metabolic dysfunction-associated steatotic liver disease (MASLD), affects an estimated one in three UK adults and ranges from simple fat accumulation to serious inflammation and scarring. Research suggests that restoring a healthier gut microbiome may reduce the inflammatory signals that drive liver damage. This article explains how probiotics might help, what the clinical evidence shows, which strains are most studied, and what safety considerations apply.

What is non-alcoholic fatty liver disease and how does it develop?

NAFLD is excess fat accumulation in liver cells unrelated to alcohol, affecting around one in three UK adults, and ranges from simple steatosis to the more serious NASH (MASH), which can progress to cirrhosis. Gut dysbiosis and increased intestinal permeability are key contributors via the gut-liver axis.

Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess fat accumulates in the liver cells of people who drink little or no alcohol. It is now one of the most common liver conditions in the UK, affecting an estimated one in three adults to some degree, according to the British Liver Trust.^[1][2] NAFLD exists on a spectrum: at its mildest, it presents as simple steatosis (fat deposits without significant inflammation), while a more advanced form, non-alcoholic steatohepatitis (NASH), involves liver cell damage and inflammation that can progress to fibrosis, cirrhosis, or liver failure.

It is worth noting that UK and European hepatology bodies, including the British Society of Gastroenterology (BSG) and the European Association for the Study of the Liver (EASL), have recently moved towards updated terminology: NAFLD is increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), and NASH as metabolic dysfunction-associated steatohepatitis (MASH). Both terms describe the same underlying conditions, and you may encounter either in clinical or patient-facing materials.

The condition develops through a combination of metabolic, dietary, and genetic factors. Obesity, type 2 diabetes, insulin resistance, and high blood triglycerides are among the strongest risk factors. When the liver is overwhelmed by excess fatty acids, particularly from a diet high in refined carbohydrates and saturated fats, fat begins to accumulate within hepatocytes. Sedentary behaviour compounds this process by reducing the body's ability to metabolise lipids efficiently.

Research has increasingly highlighted the role of the gut-liver axis in NAFLD development. The liver receives a substantial proportion of its blood supply from the gut via the portal vein, meaning that changes in gut bacteria and intestinal permeability can directly influence liver health. Dysbiosis, an imbalance in the gut microbiome, has been observed in people with NAFLD and is thought to contribute to increased translocation of bacterial products such as lipopolysaccharides into the portal circulation, triggering hepatic inflammation.^[6][7] This gut-liver connection is one reason why probiotics have attracted scientific interest as a potential supportive intervention.

If you are concerned about symptoms that may suggest liver disease, such as persistent fatigue, discomfort in the upper right abdomen, or unexplained weight changes, speak to your GP. Urgent symptoms including jaundice (yellowing of the skin or eyes), swelling of the abdomen, confusion, or vomiting blood require prompt assessment: contact NHS 111 or go to your nearest emergency department.

How might probiotics help with fatty liver disease?

Probiotics may benefit fatty liver disease by strengthening the gut barrier, reducing endotoxin translocation to the liver, modulating inflammatory cytokines, and improving insulin sensitivity through short-chain fatty acid production. They are not a replacement for dietary and lifestyle changes.

Probiotics may help with fatty liver disease primarily by restoring a healthier balance of gut bacteria, which in turn reduces the inflammatory signals reaching the liver via the portal circulation. Probiotics are live microorganisms that, when consumed in adequate amounts, confer a health benefit on the host, as defined by the World Health Organisation and the Food and Agriculture Organisation of the United Nations.

In the context of NAFLD, their proposed mechanisms are closely tied to the gut-liver axis described above. Several biological pathways have been proposed to explain how probiotics might benefit the liver:

• Reducing intestinal permeability: Certain probiotic strains appear to strengthen the tight junctions between intestinal epithelial cells, reducing the leakage of bacterial endotoxins such as lipopolysaccharide into the portal bloodstream. Lower endotoxin levels are associated with reduced hepatic inflammation.

• Modulating the immune response: Probiotics may shift the balance of immune signalling in the gut and liver away from pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-alpha) and interleukin-6, both of which are elevated in NASH.^[8][9]

• Influencing lipid and glucose metabolism: Some strains produce short-chain fatty acids (SCFAs) such as butyrate during fermentation of dietary fibre. SCFAs can improve insulin sensitivity and reduce hepatic lipogenesis (the production of new fat in the liver).^[11]

• Reducing oxidative stress: Certain probiotic species have been shown in laboratory studies to increase antioxidant enzyme activity, potentially protecting liver cells from oxidative damage.

It is important to note that these mechanisms are largely derived from preclinical and early-phase human studies. Probiotics are not a replacement for established lifestyle interventions such as dietary modification and increased physical activity, which remain the cornerstone of NAFLD management according to NICE guideline NG49 (Non-alcoholic fatty liver disease: assessment and management).^[12]

What does the evidence say about probiotics for NAFLD?

Clinical trials and meta-analyses show probiotics produce modest, statistically significant reductions in ALT, AST, cholesterol, and fasting glucose in NAFLD, but trials are short, use varied strains, and rely on surrogate markers rather than liver biopsy. NICE does not currently recommend probiotics for NAFLD.

Clinical trial evidence suggests that probiotics can produce modest improvements in liver enzyme levels and metabolic markers in people with NAFLD, though the overall evidence base remains limited and heterogeneous. Multiple randomised controlled trials and several systematic reviews and meta-analyses have examined probiotic supplementation in NAFLD, with outcomes including alanine aminotransferase (ALT), aspartate aminotransferase (AST), liver fat content measured by ultrasound or MRI, body mass index, and markers of insulin resistance.

A 2019 meta-analysis published in the journal Nutrients, which pooled data from 15 randomised controlled trials, found that probiotic supplementation was associated with statistically significant reductions in ALT, AST, total cholesterol, and fasting blood glucose compared with placebo.^[14] A further meta-analysis published in Frontiers in Nutrition in 2021 similarly reported improvements in liver steatosis scores and inflammatory markers. More recent systematic reviews published between 2022 and 2024 have broadly confirmed these findings, while continuing to highlight the limitations of the available evidence.

Reviewers consistently note important limitations across this body of research: trials are typically short (8 to 24 weeks), use different probiotic strains and doses, and rely on surrogate markers such as blood enzyme levels rather than histological confirmation of liver improvement via biopsy. The clinical significance of the observed changes in surrogate endpoints remains uncertain, and results should not be interpreted as evidence of meaningful structural liver benefit.

At present, neither NICE (NG49) nor NHS England has issued specific guidance recommending probiotics as a treatment for NAFLD.^[12][13] There is no licensed probiotic medicine for this indication in the UK. The evidence is considered promising but not yet sufficient to support routine clinical recommendation. Ongoing research, including larger trials with longer follow-up and standardised outcome measures, is needed to clarify which patient groups might benefit most and what the optimal probiotic formulation might be. People with NAFLD should discuss any supplementation with their GP or hepatology team before starting.

Which probiotic strains are most studied for liver health?

Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantarum, and Saccharomyces boulardii are the most studied strains for NAFLD, often used in multi-strain formulations. No single strain or product has been shown to be clearly superior.

The most studied probiotic strains for liver health in the context of NAFLD include species from the Lactobacillus and Bifidobacterium genera, as well as the yeast Saccharomyces boulardii. These organisms have been used in the majority of published clinical trials and have the broadest body of supporting preclinical data. Note that some species have been reclassified under updated taxonomy (for example, Lactobacillus rhamnosus is now formally Lacticaseibacillus rhamnosus), though products are still commonly labelled using the older names.

Commonly investigated strains and combinations include:

• Lactobacillus rhamnosus GG: One of the most extensively researched probiotic strains globally, with evidence suggesting benefits for gut barrier function and modest reductions in liver enzyme levels in some NAFLD trials.

• Lactobacillus acidophilus and Bifidobacterium lactis: Often used in combination, these strains have been associated with reductions in ALT and improvements in lipid profiles in short-term trials.

• Lactobacillus plantarum: Studied for its potential to reduce hepatic fat accumulation and inflammatory cytokine levels, with some positive findings in both animal models and small human trials.

• Multi-strain formulations: Several trials have used combinations of four to eight strains simultaneously, on the basis that a diverse microbial community may produce more robust effects than a single strain. Results have generally been comparable to or slightly better than single-strain preparations, though direct head-to-head comparisons are limited and no formulation has been shown to be clearly superior.

• Saccharomyces boulardii: This yeast-based probiotic has shown promise in reducing endotoxin translocation and liver inflammation in some studies, though the evidence base is smaller than for bacterial strains.^[9][15]

Probiotic effects are highly strain-specific. A product labelled simply as "Lactobacillus" may behave very differently from a named, characterised strain used in a clinical trial. Consumers should look for products that clearly state the strain designation (for example, Lactobacillus rhamnosus GG) and the colony-forming unit (CFU) count, ideally guaranteed at the end of the product's shelf life rather than at the time of manufacture. Probiotics sold in the UK as food supplements are regulated by the Food Standards Agency rather than the MHRA, and quality and labelling standards can vary between products.^[16]

Are probiotics safe to take if you have fatty liver disease?

Probiotics are generally safe for most adults with early-stage NAFLD, with side effects typically limited to mild, transient bloating or loose stools. People with cirrhosis, immunosuppression, or critical illness should seek specialist advice before use.

Probiotics are generally considered safe for most adults with NAFLD, including those with early-stage disease, and serious adverse effects are rare in the published literature. The most commonly reported side effects are mild and gastrointestinal in nature, including bloating, flatulence, and loose stools, particularly during the first one to two weeks of use as the gut microbiome adjusts. These effects typically resolve without intervention.

However, there are important safety considerations for specific groups:

• Advanced liver disease or cirrhosis: People with decompensated cirrhosis or significant immunosuppression should seek specialist advice before taking probiotics, as there are rare case reports of bacteraemia (bacteria entering the bloodstream) or fungaemia in severely immunocompromised individuals.

• Central venous catheters or critical illness: People who have a central venous catheter in place, or who are critically ill, should not take probiotics without explicit specialist advice, as these situations carry an elevated risk of bloodstream infection.^[18][19]

• Concurrent medications: Probiotics are not known to interact significantly with most medicines, but people taking immunosuppressants or antifungals should discuss supplementation with their GP or specialist.

• Pregnancy and breastfeeding: Probiotic use during pregnancy is generally considered low risk, but evidence is limited. Women who are pregnant, breastfeeding, or planning a pregnancy should consult their GP or midwife before starting any new supplement.

If you experience persistent abdominal pain, fever, or any new or worsening symptoms after starting a probiotic, contact your GP. Symptoms that may indicate serious liver disease progression, including jaundice, abdominal swelling, confusion, or vomiting blood, require urgent assessment: contact NHS 111 or go to your nearest emergency department without delay.

Healthcare professionals and patients can report any suspected adverse reactions to medicines or supplements via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Always inform your GP or hepatology team of any supplements you are taking so that your overall care can be coordinated safely.

Scientific References

1. Fatty liver disease – British Liver Trust.
2. Prevalence of steatosis and fibrosis in young adults in the UK.
3. Non-alcoholic fatty liver disease (NAFLD) – NHS.
4. EASL position paper on preclinical models of steatotic liver disease. Journal of Hepatology..
5. Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction-associated Steatotic Liver Disease: Radiologists' Perspective. Radiographics..
6. Gut microbiome in non-alcoholic fatty liver disease. Frontiers in Gastroenterology..
7. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatology International..
8. The gut-liver axis: microbial mechanisms and therapeutic implications in MAFLD. Frontiers in Cellular and Infection Microbiology..
9. Modulating the Gut-Liver Axis: Anti-Inflammatory Mechanisms of Probiotics and Prebiotics in MASLD. Probiotics and Antimicrobial Proteins..
10. Efficacy of probiotic in NAFLD mouse model. Frontiers in Immunology..
11. High-fructose diet-induced gut dysbiosis as a mechanistic driver of chronic inflammation and accelerated biological aging. Frontiers in Microbiology..
12. Metabolic dysfunction-associated steatotic liver disease: assessment and management (NG49). NICE..
13. NG49 Recommendations for research: probiotic and prebiotic supplements for NAFLD. NICE..
14. Gut Microbiota and Liver Health: Meta-Analysis of probiotic interventions in NAFLD. International Journal of Molecular Sciences..
15. The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Frontiers in Nutrition..
16. Food supplements: guidance for businesses. UK Government..
17. Probiotics – NHS.
18. Mayer S et al. Probiotic-Associated Central Venous Catheter bloodstream infections. 2023..
19. Regulatory oversight and safety of probiotic use. Emerging Infectious Diseases..

Frequently Asked Questions